Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study

Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study

Stem cell transplantation safe for patients with HIV-associated lymphoma

Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study

Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study

Children with aggressive leukaemia experiencing remission with T cell therapy

ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy

Overall survival update from the BREAK-3 study

ecancermedicalscience editor's choice for November 2014

Biomarker for PARP inhibitor responsiveness in ovarian cancer patients

New drug, ASP8273, shows response in Japanese patients with treatment-resistant non-small cell lung cancer